AU2021230103A1 - Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis - Google Patents

Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis Download PDF

Info

Publication number
AU2021230103A1
AU2021230103A1 AU2021230103A AU2021230103A AU2021230103A1 AU 2021230103 A1 AU2021230103 A1 AU 2021230103A1 AU 2021230103 A AU2021230103 A AU 2021230103A AU 2021230103 A AU2021230103 A AU 2021230103A AU 2021230103 A1 AU2021230103 A1 AU 2021230103A1
Authority
AU
Australia
Prior art keywords
human
treatment
tregs
subject
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021230103A
Other languages
English (en)
Inventor
Gilbert BENSIMON
Cecilia Garlanda
Janine KIRBY
Peter Nigel LEIGH
Massimo LOCATI
Andrea MALASPINA
Pamela Shaw
Timothy TREE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Centre Hospitalier Universitaire de Nimes
University of Sheffield
Kings College London
Queen Mary University of London
University of Sussex
Humanitas Mirasole SpA
Original Assignee
Centre Hospitalier Univ De Nimes
Assistance Publique Hopitaux de Paris APHP
Sorbonne Universite
Centre Hospitalier Universitaire de Nimes
University of Sheffield
Kings College London
Queen Mary University of London
University of Sussex
Humanitas Mirasole SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ De Nimes, Assistance Publique Hopitaux de Paris APHP, Sorbonne Universite, Centre Hospitalier Universitaire de Nimes, University of Sheffield, Kings College London, Queen Mary University of London, University of Sussex, Humanitas Mirasole SpA filed Critical Centre Hospitalier Univ De Nimes
Publication of AU2021230103A1 publication Critical patent/AU2021230103A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2021230103A 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis Pending AU2021230103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305241.0 2020-03-06
EP20305241 2020-03-06
PCT/EP2021/055570 WO2021176044A1 (en) 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
AU2021230103A1 true AU2021230103A1 (en) 2022-09-22

Family

ID=71083549

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021230103A Pending AU2021230103A1 (en) 2020-03-06 2021-03-05 Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis

Country Status (8)

Country Link
US (2) US20230090069A1 (https=)
EP (2) EP4647123A3 (https=)
JP (1) JP7840267B2 (https=)
AU (1) AU2021230103A1 (https=)
CA (1) CA3166887A1 (https=)
ES (1) ES3041723T3 (https=)
TW (1) TWI894224B (https=)
WO (1) WO2021176044A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630035A1 (en) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Also Published As

Publication number Publication date
EP4114440C0 (en) 2025-06-25
US20230090069A1 (en) 2023-03-23
JP7840267B2 (ja) 2026-04-03
CA3166887A1 (en) 2021-09-10
EP4114440B1 (en) 2025-06-25
TW202146041A (zh) 2021-12-16
EP4647123A3 (en) 2025-12-24
JP2023516774A (ja) 2023-04-20
US20240335510A1 (en) 2024-10-10
EP4647123A2 (en) 2025-11-12
ES3041723T3 (en) 2025-11-14
WO2021176044A1 (en) 2021-09-10
EP4114440A1 (en) 2023-01-11
TWI894224B (zh) 2025-08-21

Similar Documents

Publication Publication Date Title
EP3443979B1 (en) Il-2 dosage regimen for treating systemic lupus erythematosus
Vastert et al. Anakinra in children and adults with Still’s disease
US20240335510A1 (en) Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
US10293028B2 (en) Use of low dose IL-2 for treating autoimmune related or inflammatory disorders
Plosker Interferon-β-1b: a review of its use in multiple sclerosis
McMichael et al. A phase I/II trial of cetuximab in combination with interleukin-12 administered to patients with unresectable primary or recurrent head and neck squamous cell carcinoma
JP2018512164A (ja) 骨髄増殖性障害を処置するための方法
Marwaha et al. A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes
Phan et al. Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses
KR20190071785A (ko) 인터페론 감마 관련 적응증의 치료 또는 예방을 위한 방법, 조성물 및 투여 요법
McBride et al. Triggers, timescales, and treatments for cytokine-mediated tissue damage
US20120252896A1 (en) Methods and compositions for modulation of t-cells via the kynurenine pathway
Heath et al. Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
US20110044939A1 (en) Regulatory t cells in adipose tissue
Svanberg Teglgaard et al. Improved innate immune function in patients with chronic lymphocytic leukemia treated with targeted therapy in clinical trials
Fabris et al. Study on the possible role of the-174G> C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis
PARK et al. Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: Results of a first-in-human Phase 1 trial
Topping et al. sclerosis, Multiple Sclerosis and Related Disorders
EA042261B1 (ru) Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний